VRCA vs. STTK, KRRO, NGNE, ESPR, MREO, TERN, HRTX, ANRO, ORGO, and AMRN
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Shattuck Labs (STTK), Korro Bio (KRRO), Neurogene (NGNE), Esperion Therapeutics (ESPR), Mereo BioPharma Group (MREO), Terns Pharmaceuticals (TERN), Heron Therapeutics (HRTX), Alto Neuroscience (ANRO), Organogenesis (ORGO), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Shattuck Labs (NASDAQ:STTK) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
Verrica Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 15 mentions for Verrica Pharmaceuticals and 11 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.54 beat Verrica Pharmaceuticals' score of 0.36 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 10.5% of Shattuck Labs shares are held by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Shattuck Labs has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500.
Verrica Pharmaceuticals has a net margin of -905.83% compared to Verrica Pharmaceuticals' net margin of -3,133.63%. Verrica Pharmaceuticals' return on equity of -64.85% beat Shattuck Labs' return on equity.
Shattuck Labs currently has a consensus price target of $20.00, suggesting a potential upside of 152.68%. Verrica Pharmaceuticals has a consensus price target of $13.50, suggesting a potential upside of 55.71%. Given Verrica Pharmaceuticals' higher probable upside, equities research analysts plainly believe Shattuck Labs is more favorable than Verrica Pharmaceuticals.
Verrica Pharmaceuticals received 134 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 76.32% of users gave Shattuck Labs an outperform vote while only 64.94% of users gave Verrica Pharmaceuticals an outperform vote.
Summary
Verrica Pharmaceuticals beats Shattuck Labs on 9 of the 17 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
